论文部分内容阅读
目的:评价吉西他滨联合奥沙利铂(Gemox)在复发难治性淋巴瘤患者中的疗效和安全性。方法:回顾性分析Gemox方案进行化疗的30例复发难治性淋巴瘤患者疗效及安全性。结果:28例可评价患者近期疗效中,完全缓解7例(25.0%),部分缓解8例(28.6%),稳定8例(28.6%),进展5例(17.8%),总缓解率为53.6%。全组中位无进展生存时间(PFS)为11个月,15例OR患者的中位PFS为26个月。不良反应主要为骨髓抑制和肝功能损伤,其中出现Ⅲ-Ⅳ°中性粒细胞减少15例(53.6%),出现ALT/AST>两倍正常值5例(17.6%)。既往化疗达缓解的再次复发化疗敏感性更高,差异有统计学意义。结论:Gemox方案对于复发难治性淋巴瘤患者有较高的缓解率,既往化疗敏感的淋巴瘤患者获益可能性更大。
Objective: To evaluate the efficacy and safety of gemcitabine combined with Gemox in relapsed and refractory lymphoma patients. Methods: The curative effect and safety of Gemox regimen in 30 patients with refractory lymphoma were retrospectively analyzed. Results: Among 28 evaluable patients, complete remission was achieved in 7 cases (25.0%), partial remission in 8 cases (28.6%), stabilization in 8 cases (28.6%) and progression in 5 cases (17.8%) with a total remission rate of 53.6 %. The median overall progression-free survival time (PFS) was 11 months and the median PFS for 15 OR patients was 26 months. Adverse reactions were mainly myelosuppression and hepatic impairment. There were 15 cases (53.6%) with Ⅲ-Ⅳ ° neutropenia and 5 cases (17.6%) with twice normal ALT / AST. Previous chemoradiotherapy re-recurrence chemotherapy more sensitive, the difference was statistically significant. CONCLUSIONS: The Gemox regimen has a high remission rate in patients with relapsed refractory lymphoma, with a greater likelihood of benefit from previously chemosensitive lymphomas.